The investment in Expercy for this case amounts to NT$100 million, with its primary products being Diviup® Absorbable Adhesion Barrier Film, Guided Tissue Regeneration Membrane (GTR membrane), and ConoSpina Spine Anti-Adhesion Gel.
The company in question is committed to solving the application bottlenecks in existing minimally invasive surgeries. The multi-functional, temperature-sensitive hydrogel they developed possesses breakthrough technology: it is liquid at room temperature and rapidly forms a stable gel in vivo after injection. This effectively reduces the incidence and degree of adhesion after spinal surgery. Furthermore, in terms of high-end anti-adhesion medical devices, the company has optimized the design to address operational issues found in commercially available products. Future plans include incorporating a drug delivery and release system, which will expand its clinical applications.
The company has established a high-end medical device development platform with significant commercialization potential. Following its relocation to the science park, the company will continue to drive the R&D of high-value-added medical devices and will strengthen cooperation with surrounding medical institutions. This effort will contribute to enhancing domestic medical quality and self-sufficiency, as well as boosting the technical capacity and international market competitiveness of the domestic high-end medical device sector.
Link: 國科會第25次園區審議會核准投資案(竹科) – -訊息公告 (Source: Hsinchu Science Park)